
Health Canada approves 1st GLP-1 daily pill. Here’s who can take it
Global News
The once-a-day semaglutide pill is approved for reducing the risk of heart disease and Type 2 diabetes, the company said in a statement Monday.
Health Canada has approved a GLP-1 pill for the first time.
The once-a-day semaglutide pill is approved for reducing the risk of heart disease and Type 2 diabetes, the company said in a statement Monday.
Rybelsus is a glucagon-like peptide-1 (GLP-1) drug, the same type of medication as injectables Ozempic and Wegovy by the same manufacturer.
All other GLP-1 drugs available in Canada are injectables to date.
The pill has only been approved for adults with Type 2 diabetes who also have a cardiovascular disease or are at high risk for heart disease, though Novo Nordisk has applied to bring a separate pill form of weight loss medication Wegovy to Canada as well.
Novo Nordisk says its trial of Rybelsus included 9,650 patients who were randomized to receive either Rybelsus 14 mg or the placebo daily. The trial showed that the use of Rybelsus lowered the risk of cardiovascular events, like heart attacks, the company says.
The pill can work “along with diet and exercise to improve blood sugar (glucose) in adults with type 2 diabetes,” the Rybelsus website says.
It can also be used to “reduce the risk of major cardiovascular events such as heart attack, stroke or death in adults with type 2 diabetes mellitus who are at high risk for these events,” the website says.













